Publicaciones (25) Publicaciones de MOISES DIAGO MADRID

2024

  1. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease

    Journal of Hepatology, Vol. 80, Núm. 3, pp. 419-430

  2. Opportunistic population screening as a hepatitis elimination strategy: the CRIVALVIR-FOCUS program

    International Journal of Infectious Diseases, Vol. 146

  3. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 2, pp. 201-211

  4. The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease

    JHEP Reports, Vol. 6, Núm. 7

2023

  1. Outcomes of an automated alert system from Microbiology to link diagnosis to treatment in patients with hepatitis C virus

    Revista espanola de enfermedades digestivas, Vol. 115, Núm. 4, pp. 181-187

2022

  1. Assessment of liver damage in patients with COVID-19 is sub-optimal: results of a survey of medical practitioners

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva

  2. One-step diagnosis strategy together with multidisciplinary telematics referral perform an effective approach for identifying and treating patients with active Hepatitis C infection

    Annals of Hepatology, Vol. 27, Núm. 1

2021

  1. Abnormal liver chemistry constitutes an independent prognostic factor of less favorable clinical course in patients with COVID-19

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 113, Núm. 12, pp. 825-832

  2. Can secukinumab improve liver fibrosis? A pilot prospective study of 10 psoriatic patients

    Dermatologic Therapy

2020

  1. Hepatic encephalopathy due to a congenital portosystemic shunt: A disease with a changeable presentation

    Revista Espanola de Enfermedades Digestivas

  2. Prevalence of non-alcoholic fatty liver and liver fibrosis in patients with moderate–severe psoriasis: A cross-sectional cohort study

    Australasian Journal of Dermatology, Vol. 61, Núm. 2, pp. 105-109

2017

  1. Co-20. Validación de los índices fib 4 y nfs para discriminar fibrosis hepática en pacientes con eghna en práctica clínica habitual.

    Revista andaluza de patología digestiva, Vol. 40, Núm. 5, pp. 282-283

  2. Gastrointestinal bleeding and acute hepatic failure by leptospirosis: an entity that should not be forgotten

    Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru, Vol. 37, Núm. 1, pp. 96-99

2013

  1. 18. Las variantes de pnpla3 promueven la esteatosis en función del genotipo viral y la ilb28 sin afectar a la respuesta viral sostenida en pacientes con hepatitis c.

    Revista andaluza de patología digestiva, Vol. 36, Núm. 5, pp. 344-344

2012

  1. 5. Interacción entre los genotipos virales y del hospedador influenciados por la infección del virus de la hepatitis C

    Revista andaluza de patología digestiva, Vol. 35, Núm. 5, pp. 400-400

2011

  1. SUBANALYSES OF THE TELAPREVIR LEAD-IN ARM IN THE REALIZE STUDY: RESPONSE AT WEEK 4 IS NOT A SUBSTITUTE FOR PRIOR NULL RESPONSE CATEGORIZATION

    SWISS MEDICAL WEEKLY

  2. Telaprevir-based therapy in G1 HCV-infected patients with prior null response, partial response or relapse to peginterferon/ribavirin: REALIZE trial final results

    SWISS MEDICAL WEEKLY

2007

  1. Hepatitis crónica C: tratamiento en el 2006

    Revista andaluza de patología digestiva, Vol. 30, Núm. 1, pp. 34-40

2006

  1. Tratamiento de pacientes genotipo 4

    Gastroenterologia y Hepatologia

2005

  1. Rentabilidad de la ecografía abdominal en el diagnóstico del carcinoma colorrectal

    Revista Espanola de Enfermedades Digestivas